Among patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation, those who received osimertinib had longer overall survival than those who received a compar...
In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the p...
Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppressi...